Epigenomics confident of achieving FY05 guidance despite Q3 revenue loss
This article was originally published in Clinica
In spite of its success at costs control, German molecular diagnostics company Epigenomics saw its third-quarter 2005 top-line fall 28% to Euro2.1m ($2.5m) from last year's level. The firm also widened its net loss for the period by 6% to Euro2.8m.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.